DE60137915D1 - Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität - Google Patents

Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität

Info

Publication number
DE60137915D1
DE60137915D1 DE60137915T DE60137915T DE60137915D1 DE 60137915 D1 DE60137915 D1 DE 60137915D1 DE 60137915 T DE60137915 T DE 60137915T DE 60137915 T DE60137915 T DE 60137915T DE 60137915 D1 DE60137915 D1 DE 60137915D1
Authority
DE
Germany
Prior art keywords
cadherin
human
antibody
cadherine
negative effects
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60137915T
Other languages
English (en)
Inventor
Fang Liao
Daniel J Hicklin
Peter Bohlen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ImClone LLC
Original Assignee
ImClone Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ImClone Systems Inc filed Critical ImClone Systems Inc
Application granted granted Critical
Publication of DE60137915D1 publication Critical patent/DE60137915D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE60137915T 2000-03-31 2001-03-30 Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität Expired - Lifetime DE60137915D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54096700A 2000-03-31 2000-03-31
PCT/US2001/010505 WO2001075109A2 (en) 2000-03-31 2001-03-30 Antagonist antibodies to ve-cadherin without adverse effects on vascular permeability

Publications (1)

Publication Number Publication Date
DE60137915D1 true DE60137915D1 (de) 2009-04-23

Family

ID=24157649

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60137915T Expired - Lifetime DE60137915D1 (de) 2000-03-31 2001-03-30 Antagonistische antikörper gegen ve-cadherin ohne negative effekte auf die vaskuläre permeabilität

Country Status (12)

Country Link
US (4) US7371574B2 (de)
EP (1) EP1268799B1 (de)
JP (1) JP2003529370A (de)
AT (1) ATE425255T1 (de)
AU (1) AU2001249737A1 (de)
CA (1) CA2404576A1 (de)
CY (1) CY1109097T1 (de)
DE (1) DE60137915D1 (de)
DK (1) DK1268799T3 (de)
ES (1) ES2323938T3 (de)
PT (1) PT1268799E (de)
WO (1) WO2001075109A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
CA2506037A1 (en) * 2002-11-14 2004-06-10 Adherex Technologies, Inc. Compounds and methods for modulating desmosomal and atypical cadherin-mediated cell adhesion
JP2004175689A (ja) * 2002-11-25 2004-06-24 Kureha Chem Ind Co Ltd 癌転移抑制剤
US20040167076A1 (en) 2003-02-14 2004-08-26 Stamer W. Daniel Modulation of aqueous humor outflow by targeting vascular-endothelial-cadherin in schlemm's canal cells
GB0602063D0 (en) 2006-02-02 2006-03-15 Univ Manchester Cell Culture
US9207242B2 (en) * 2008-10-09 2015-12-08 The University Of Hong Kong Cadherin-17 as diagnostic marker and therapeutic target for liver cancer
WO2011071541A2 (en) * 2009-12-11 2011-06-16 The Scripps Research Institute Cadherin modulatory agents

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946778A (en) * 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5036003A (en) * 1987-08-21 1991-07-30 Monsanto Company Antibodies to VPF
AU2861692A (en) * 1991-10-18 1993-05-21 Beth Israel Hospital Association, The Vascular permeability factor targeted compounds
US5660827A (en) * 1992-03-05 1997-08-26 Board Of Regents, The University Of Texas System Antibodies that bind to endoglin
US6004555A (en) * 1992-03-05 1999-12-21 Board Of Regents, The University Of Texas System Methods for the specific coagulation of vasculature
US5877289A (en) * 1992-03-05 1999-03-02 The Scripps Research Institute Tissue factor compositions and ligands for the specific coagulation of vasculature
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
WO1993017715A1 (en) * 1992-03-05 1993-09-16 Board Of Regents, The University Of Texas System Diagnostic and/or therapeutic agents, targeted to neovascular endothelial cells
US5646250A (en) * 1992-04-17 1997-07-08 Doheny Eye Institute Cadherin polypeptides
WO1993021302A1 (en) * 1992-04-17 1993-10-28 Doheny Eye Institute Cadherin materials and methods
US5597725A (en) * 1992-04-17 1997-01-28 Doheny Eye Institute Cadherin-specific antibodies and hybridoma cell lines
US5840301A (en) * 1994-02-10 1998-11-24 Imclone Systems Incorporated Methods of use of chimerized, humanized, and single chain antibodies specific to VEGF receptors
US5861499A (en) * 1994-02-10 1999-01-19 Imclone Systems Incorporated Nucleic acid molecules encoding the variable or hypervariable region of a monoclonal antibody that binds to an extracellular domain
US5730977A (en) * 1995-08-21 1998-03-24 Mitsui Toatsu Chemicals, Inc. Anti-VEGF human monoclonal antibody
US20050222037A1 (en) * 1998-05-05 2005-10-06 Adherex Technologies, Inc. Compounds and methods for modulating VE-cadherin-mediated function
US6433149B1 (en) * 1998-05-05 2002-08-13 Adherex Technologies, Inc. Compounds and methods for inhibiting cancer metastasis
US20030206902A1 (en) * 2001-03-05 2003-11-06 Fang Liao Ve-cadherin and vegfr-2 antagonists for therapeutic modulation of angiogenesis

Also Published As

Publication number Publication date
WO2001075109A3 (en) 2002-05-16
DK1268799T3 (da) 2009-07-06
CA2404576A1 (en) 2001-10-11
PT1268799E (pt) 2009-05-11
US20020160003A1 (en) 2002-10-31
US7371574B2 (en) 2008-05-13
EP1268799B1 (de) 2009-03-11
ATE425255T1 (de) 2009-03-15
CY1109097T1 (el) 2014-07-02
US20080317750A1 (en) 2008-12-25
JP2003529370A (ja) 2003-10-07
US20080311121A1 (en) 2008-12-18
ES2323938T3 (es) 2009-07-28
WO2001075109A2 (en) 2001-10-11
EP1268799A2 (de) 2003-01-02
AU2001249737A1 (en) 2001-10-15
US20090060909A1 (en) 2009-03-05

Similar Documents

Publication Publication Date Title
CY1109097T1 (el) Ανταγωνιστες αντισωματων ve-καντερινης χωρις αρνητικες επιδρασεις επι αγγειακης διαπερατοτητας
DK0528767T3 (da) antistofderivater
DE69735294D1 (de) Spezifische monoklonale antikörperfür die extrazelluläre domäne von protasta-spezifischem membranantigen
WO2005103698A3 (en) Methods and antibodies for nitrofuran detection
ATE158415T1 (de) Kationisierte antikörper gegen intrazelluläre eiweisse
ES2082775T4 (es) Anticuerpos de proteinas latentes de papilomavirus humano, sistemas de diagnostico y procedimientos.
NL300067I1 (nl) Gemodificeerde antilichamen.
DE68918497D1 (de) Monoklonale Mäuseantikörper gegen HIV-IP24 und ihre Verwendung in Diagnostika.
ES2121792T3 (es) Anticuerpo monoclonal.
NZ288235A (en) Monoclonal antibody directed against the receptor tyrosine kinase flt4 and use in diagnosis and therapy
IT1257893B (it) Anticorpi monoclonali che riconoscono un epitopo della p-glicoproteina umana.
NL7901755A (nl) Biologisch-gas-, ethanol-gas- of ademtester.
DE3889581D1 (de) Monoklonale Antikörper gegen spezifische antigene Regionen des humanen Immundefizienzvirus und Methoden zur Verwendung.
FI922666A0 (fi) Diagnostiskt foerfarande.
AU4661293A (en) Peptides representing antigenic epitopes of ige present on b cell but not basophil surface
DE69430313D1 (de) Monoklonale antikörper, die flk-2-rezeptoren erkennen, und die isolierung primitiver hämatopoietischer stammzellpopulationen
DE69132144D1 (de) Menschliche phospholipase aktivierender proteinteil
AR023204A1 (es) Anticuerpos contra la proteina placentaria 13.
WO2003061575A3 (en) Anti-idiotype antibody of disintegrin and uses thereof
ATE343596T1 (de) Humane monoklonale antikörper gegen inselzellantigen ia-2
DE69111429D1 (de) Monoklonale antikörper, die einen unterschied zwischen nativproteinen und proteinen mit einer modifizierten sequenz machen.
ATE169332T1 (de) Monoklonaler antikörper gegen den extravillösen trophoblast
Pawlikowski Religion and American Public Life. Edited by Robin Lovin. New York: Paulist Press, 1986. Pp. 181. Paper. $8.95. ISBN: 0-8091-2815-2.
Davisson Invisible owners of painted ladies and other homes: Women property owners in Nevada City, California, 1856-1876.
全秀池 An Open Problem about Complemented Subspace

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: IMCLONE LLC, DOVER, DEL., US

8364 No opposition during term of opposition
R082 Change of representative

Ref document number: 1268799

Country of ref document: EP

Representative=s name: DR. SCHOEN & PARTNER, DE